Evidence [17–20] suggests that programmed death-ligand-1 (PD-L1), an immune checkpoint ligand, represses anti-tumor immunity through its interaction with the programmed death factor 1 (PD-1) receptor of T lymphocytes in various tumors. The gene discussed is CD274; the disease is neoplasm.